Table 1 Baseline patient information and clinical features
Characteristics | Before PSM | After PSM | ||||||
|---|---|---|---|---|---|---|---|---|
Total (N = 419) | AAPR≤0.4 (N = 173) | AAPR> 0.4 (N = 246) | P-value | Total (N = 312) | AAPR≤0.4 (N = 156) | AAPR> 0.4 (N = 156) | P-value | |
Age | ||||||||
  ≤ 60 | 200 (47.7) | 78 (45.1) | 122 (49.6) | 0.373 | 136 (43.6) | 72 (46.2) | 64 (41.0) | 0.424 |
  > 60 | 219 (52.3) | 95 (54.9) | 124 (50.4) |  | 176 (56.4) | 84 (53.8) | 92 (59.0) |  |
Sex | ||||||||
 Male | 269 (64.2) | 108 (62.4) | 161 (65.4) | 0.536 | 195 (62.5) | 99 (63.5) | 96 (61.5) | 0.815 |
 Female | 150 (35.8) | 65 (37.6) | 85 (34.6) |  | 117 (37.5) | 57 (36.5) | 60 (38.5) |  |
Tumor location | ||||||||
 Head | 177 (42.2) | 83 (48.0) | 94 (38.2) | 0.056 | 137 (43.9) | 66 (42.3) | 71 (45.5) | 0.648 |
 Body/tail | 242 (57.8) | 90 (52.0) | 152 (61.8) |  | 175 (56.1) | 90 (57.7) | 85 (54.5) |  |
Stage | ||||||||
 III | 83 (19.8) | 22 (12.7) | 61 (24.8) | 0.003 | 50 (16.0) | 22 (14.1) | 28 (17.9) | 0.441 |
 IV | 336 (80.2) | 151 (87.3) | 185 (75.2) |  | 262 (84.0) | 134 (85.9) | 128 (82.1) |  |
CA19–9 (U/mL) | ||||||||
  ≤ 1000 | 247 (58.9) | 85 (49.1) | 162 (65.9) | 0.001 | 170 (54.5) | 85 (54.5) | 85 (54.5) | 1.000 |
  > 1000 | 172 (41.1) | 88 (50.9) | 84 (34.1) |  | 142 (45.5) | 71 (45.5) | 71 (45.5) |  |
ALB (g/L) | ||||||||
  ≤ 35 | 26 (6.2) | 20 (11.6) | 6 (2.4) | < 0.001 | 20 (6.4) | 17 (10.9) | 3 (1.9) | 0.002 |
  > 35 | 393 (93.8) | 153 (88.4) | 240 (97.6) |  | 292 (93.6) | 139 (89.1) | 153 (98.1) |  |
ALP (U/L) | ||||||||
  ≤ 125 | 296 (70.6) | 51 (29.5) | 245 (99.6) | < 0.001 | 204 (65.4) | 49 (31.4) | 155 (99.4) | < 0.001 |
  > 125 | 123 (29.4) | 122 (70.5) | 1 (0.4) |  | 108 (34.6) | 107 (68.6) | 1 (0.6) |  |